A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
Epistemonikos ID: 80caba5e34d3ee366daef7bd5a479d4091d69221
First added on: Feb 19, 2024